Clinical studies at the Berlin site

ABCD (Evaluation of the efficacy and safety of Rituximab in patients with Amyotrophic Lateral Sclerosis (ALS))

The aim of this study is to investigate the influence of rituximab (Rixathon®) on the progression of disease in patients with amyotrophic lateral sclerosis (ALS) compared to a placebo. The study is funded by the German Federal Ministry of Education and Research (BMBF).

DANCER (Establishment of a Recruitment Pool of Potential Study Participants, of Realtives and a Control Group for DZNE Studies)

One focus of these studies is the identification of early, specific changes, for example in the blood, so that the diagnosis of a neurodegenerative disease such as dementia or Parkinson's can be made at a very early stage. This enables a better understanding of the diseases and supports the development of new forms of therapy.

DANCER-FTD (Recruitment of Realtives and a Control Group for the DESCRIBE-FTD Study)

In order for us to assess study outcomes of patients with neurological frontotemporal dementia (FTD), comparative studies with relatives of patients with FTD as well as interested individuals without a diagnosis of neurodegenerative disease are needed.

DANCER-PSP (Recruitment of Realtives and a Control Group for the DESCRIBE-PSP Study)

Comparative studies with relatives of patients with PSP and interested individuals without a diagnosis of neurodegenerative disease are needed to assess study outcomes of patients with progressive supranuclear palsy (PSP).

DESCRIBE (DZNE - Clinical Register Study of neurodegenerative Disorders)

The aim of the DESCRIBE study is to use the examination results obtained in the course of normal patient care together with findings from diagnostics on biomaterials, including genetic analysis, for scientific purposes.

DESCRIBE-Cognition (DZNE - Klinische Registerstudie zur kognitiven Leistungsfähigkeit bei Alzheimer-Erkrankungen)

Alzheimer's disease is the most common cause of dementia. Although research has made progress in recent years, there are still many unanswered questions, particularly regarding the progression of the disease and early changes.

DESCRIBE-FTD/ALS (DZNE Clinical Registry Study on Frontotemporal Dementia (FTD) & on Amyotrophic lateral sclerosis (ALS))

The aims of this studies are to describe the course of FTD and ALS in detail, in their various characteristic clinical forms, to improve our understanding of the underlying pathology and to identify effective parameters for diagnosis and forecasting of the diseases' progression. This work is expected to illuminate the causes of the diseases, and to provide a basis for better therapies that can be applied at earlier stages of the diseases.

DESCRIBE-PSP (DZNE - Clinical Registry Study on Progressive Supranuclear Paresis (PSP))

The aim of the DESCRIBE-PSP study is to document the early and atypical course of PSP in order to enable improved diagnostic criteria and therapy studies in the early course of the disease.

DESCRIBE-Treatment (DZNE - Clinical Registry Study on the documentation of innovative therapies)

The DZNE therefore aims to examine participants over time through regular assessments as part of this study. The study is open to people who are being treated with newly approved therapies or new therapies that become available in the future.

DZNE-CAA (DZNE Cerebral Amyloid Angiopathy Study)

Cerebral amyloid angiopathy (CAA) is a disease of the vessels in the brain in which proteins, known as amyloid, are deposited in the walls of the vessels. There are initial indications of possible mechanisms and biomarkers that influence the course of the disease, but there are still many unanswered questions.

EfgaDem (A double-blinded, randomized, placebo-controlled, multi-center trial of Efgartigimod in autoimmune dementia)

In this clinical trial, it will be examined whether treating participants with progressive cognitive impairment or dementia with the drug Efgartigimod leads to stabilization or improvement of cognitive impairment, or to a slower rate of its progression.

ENABLE (Patient- and care-related benefits of amyloid PET imaging)

The aim of the ENABLE trial is to test whether amyloid PET screening has the potential to improve the care of dementia patients in the German health care system and thus contribute to the preservation or slowed loss of everyday functions.

PROMINENT (Improving the management of Alzheimer’s disease)

PROMINENT is a collaborative pan-European public-private partnership funded through the Innovative Health Initiative (IHI). It will create a digital platform for precision medicine to improve the diagnosis and treatment of neurodegenerative disease and co-morbidities to assist clinicians with individualised decision support in the evaluation of patients with suspected cognitive impairment.